VYNE - VYNE Therapeutics Inc. Stock Price, Fair Value and News

$0.37+0.01 (+2.78%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VYNE Price Action

Last 7 days

-2.6%

Last 30 days

5.7%

Last 90 days

19.4%

Trailing 12 Months

-86.9%

VYNE RSI Chart

VYNE Valuation

Market Cap

9.4M

Price/Earnings (Trailing)

-0.24

Price/Sales (Trailing)

19.8

EV/EBITDA

0.35

Price/Free Cashflow

-0.24

VYNE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VYNE Fundamentals

VYNE Revenue

Revenue (TTM)

476.0K

Rev. Growth (Yr)

-65.15%

Rev. Growth (Qtr)

-65.84%

VYNE Earnings

Earnings (TTM)

-38.5M

Earnings Growth (Yr)

38.82%

Earnings Growth (Qtr)

33.17%

VYNE Profitability

EBT Margin

-8091.81%

Return on Equity

-99.13%

Return on Assets

-86.2%

Free Cashflow Yield

-422.01%

VYNE Investor Care

Shares Dilution (1Y)

72.70%

Diluted EPS (TTM)

-0.89

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	605.0K	476.0K	0	0
2024	423.0K	486.0K	493.0K	501.0K
2023	398.0K	407.0K	354.0K	424.0K
2022	879.0K	710.0K	744.0K	477.0K
2021	16.0M	11.0M	5.9M	931.0K
2020	1.9M	13.6M	16.8M	21.0M
2019	2.8M	2.0M	1.2M	443.0K
2018	4.3M	4.1M	3.8M	3.6M
2017	1.1M	1.6M	2.3M	4.6M
2016	0	0	0	674.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About VYNE Therapeutics Inc.

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

CEO	Mr. David T. Domzalski
WEBSITE	vynetherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	12

VYNE Therapeutics Inc. Frequently Asked Questions

What is the ticker symbol for VYNE Therapeutics Inc.? What does VYNE stand for in stocks?

VYNE is the stock ticker symbol of VYNE Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of VYNE Therapeutics Inc. (VYNE)?

As of Wed Dec 03 2025, market cap of VYNE Therapeutics Inc. is 9.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VYNE stock?

You can check VYNE's fair value in chart for subscribers.

Is VYNE Therapeutics Inc. a good stock to buy?

The fair value guage provides a quick view whether VYNE is over valued or under valued. Whether VYNE Therapeutics Inc. is cheap or expensive depends on the assumptions which impact VYNE Therapeutics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VYNE.

What is VYNE Therapeutics Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, VYNE's PE ratio (Price to Earnings) is -0.24 and Price to Sales (PS) ratio is 19.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VYNE PE ratio will change depending on the future growth rate expectations of investors.